Maze Therapeutics disclosed positive topline Phase 2 data for MZE829, an oral dual-mechanism APOL1 inhibitor, in patients with APOL1-mediated kidney disease. In the Horizon study, Maze reported a clinically meaningful average 35.6% reduction in urine protein levels at week 12 as measured by urinary albumin-to-creatinine ratio. Maze said it will continue patient enrollment and plans regulator discussions to advance into a pivotal program, aiming to compete in a rare, genetically defined kidney disease area where Vertex’s program is currently viewed as the lead benchmark. Analysts described the results as carrying “best-in-class potential,” though the stock reaction reflected ongoing investor sensitivity to trial-to-trial risk. The company also reported subgroup responses, including larger proteinuria reductions in focal segmental glomerulosclerosis patients, supporting its plan to broaden and formalize the clinical path for APOL1-driven disease.